Insight

CAR T-cells simultaneously targeting CD276 and FGFR4 in pediatric rhabdomyosarcoma

Photo taken from volusonclub.net

Jul 28, 2024, 12:41

CAR T-cells simultaneously targeting CD276 and FGFR4 in pediatric rhabdomyosarcoma

Katherine Masih, , shared a paper by Meijie Tian et al. on X, adding:

“Check out the latest manuscript from Javed Khan’s group describing CAR T-cells simultaneously targeting CD276 and FGFR4 in pediatric rhabdomyosarcoma out now in Nature Communications!

Huge congratulations to Meijie and the team.”

Source: Katherine Masih/X

CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma.

Authors: Meijie Tian, Jun S. Wei, Adam Tai-Chi Cheuk, David Milewski Zhongmei Zhang, Yong Yean Kim, Hsien-Chao Chou, Can Liu Sherif Badr, Eleanor G. Pope, Abdelrahman Rahmy, Jerry T. Wu, Michael C. Kelly, Xinyu Wen and Javed Khan.

Abdelrahman Rahmy Adam Tai-Chi Cheuk Can Liu Sherif Badr cancer CD276 David Milewski Zhongmei Zhang Eleanor G. Pope FGFR4 Hsien-Chao Chou Javed Khan Jerry T. Wu Jun S. Wei Katherine Masih Meijie Tian Michael C. Kelly Nature Communications OncoDaily Oncology Pediatric Rhabdomyosarcoma Stanford University School of Medicine Xinyu Wen Yong Yean Kim

Padraic O’Malley: Meet the Experts of VIRO 2025

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen